No Data
Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Cautious Optimism for Design Therapeutics Amid Promising Developments and Financial Challenges
RBC Capital Remains a Hold on Design Therapeutics (DSGN)
Design Therapeutics Reports Q3 EPS (23c), Consensus (24c)